- Home
- PBPB vs TNGX Comparison
PBPB vs TNGX Comparison
Compare PBPB & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBPB
- TNGX
- Stock Information
- Founded
- PBPB 1977
- TNGX 2014
- Country
- PBPB United States
- TNGX United States
- Employees
- PBPB N/A
- TNGX N/A
- Industry
- PBPB Restaurants
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- PBPB Consumer Discretionary
- TNGX Health Care
- Exchange
- PBPB Nasdaq
- TNGX Nasdaq
- Market Cap
- PBPB 305.0M
- TNGX 351.2M
- IPO Year
- PBPB 2013
- TNGX N/A
- Fundamental
- Price
- PBPB $12.25
- TNGX $5.02
- Analyst Decision
- PBPB Strong Buy
- TNGX Strong Buy
- Analyst Count
- PBPB 3
- TNGX 6
- Target Price
- PBPB $15.67
- TNGX $12.20
- AVG Volume (30 Days)
- PBPB 233.9K
- TNGX 4.0M
- Earning Date
- PBPB 08-07-2025
- TNGX 08-06-2025
- Dividend Yield
- PBPB N/A
- TNGX N/A
- EPS Growth
- PBPB 1009.90
- TNGX N/A
- EPS
- PBPB 1.39
- TNGX N/A
- Revenue
- PBPB $465,126,000.00
- TNGX $40,990,000.00
- Revenue This Year
- PBPB $4.74
- TNGX N/A
- Revenue Next Year
- PBPB $4.48
- TNGX N/A
- P/E Ratio
- PBPB $8.82
- TNGX N/A
- Revenue Growth
- PBPB N/A
- TNGX 10.09
- 52 Week Low
- PBPB $6.28
- TNGX $1.03
- 52 Week High
- PBPB $13.48
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- PBPB 65.44
- TNGX 69.44
- Support Level
- PBPB $10.51
- TNGX $4.70
- Resistance Level
- PBPB $12.18
- TNGX $5.63
- Average True Range (ATR)
- PBPB 0.43
- TNGX 0.60
- MACD
- PBPB 0.04
- TNGX -0.01
- Stochastic Oscillator
- PBPB 80.84
- TNGX 65.38
About PBPB Potbelly Corporation
Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.